# A single-center, double-blind, randomized, placebo-controlled, 13-week study to evaluate the efficacy and safety of one capsule of XTEND-LIFE compared to placebo, and an extended four-week trial to assess its benefit when combined with ezetimibe 10 mg per day

Submission date	Recruitment status	<ul><li>Prospectively registered</li></ul>
23/03/2006	No longer recruiting	Protocol
Registration date	Overall study status	Statistical analysis plan
27/04/2006	Completed	Results
Last Edited	Condition category	Individual participant data
02/05/2006	Nutritional, Metabolic, Endocrine	<ul><li>Record updated in last year</li></ul>

# Plain English summary of protocol

Not provided at time of registration

# **Contact information**

## Type(s)

Scientific

#### Contact name

Dr Edward Kosinski

#### Contact details

4675 Main Street
Bridgeport
United States of America
06606
+1 203 683 5111
edward\_kosinski@med3000.com

## Additional identifiers

Protocol serial number

CCR-XL001

# Study information

## Scientific Title

## Study objectives

XTEND-LIFE treatment for 12 weeks results in significantly greater reduction in low-density lipoprotein (LDL-C) than treatment with placebo. The addition of ezetimibe further enhances the efficacy of XTEND-LIFE to lower LDL-C.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Approved by the Western Institutional Review Board (WIRB) on 29/09/2005, study number: 1069148, WIRB protocol number: 20051297

## Study design

Randomized, double-blind, placebo-controlled study

## Primary study design

Interventional

## Study type(s)

Treatment

## Health condition(s) or problem(s) studied

Hypercholesterolemia

#### **Interventions**

The study will compare 12 weeks of treatment with one capsule of XTEND-LIFE to placebo. After 12 weeks, ezetimibe 10 mg/day will be added.

## Intervention Type

Drug

#### Phase

**Not Specified** 

## Drug/device/biological/vaccine name(s)

XTEND LIFE Capasule and ezetimibe

## Primary outcome(s)

To compare the low density lipoprotein cholesterol (LDL-C) lowering efficacy of XTEND-LIFE to placebo in patients with hypercholesterolemia

## Key secondary outcome(s))

1. To evaluate the effect of XTEND-LIFE compared to placebo on total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), triglycerides, non-HDL-C, LDL-C:HDL-C ratio, apolipoprotein-B, apolipoprotein-A1, and high sensitivity C reactive protein

- 2. To evaluate the effect of XTEND-LIFE plus ezetimibe compared to ezetimibe and placebo on total cholesterol (TC), LDL-C, high density lipoprotein cholesterol (HDL-C), triglycerides, non-HDL-C, LDL-C:HDL-C ratio, apolipoprotein-B, apolipoprotein-A1, and high sensitivity C reactive protein
- 3. To explore the safety and tolerability of XTEND-LIFE with and without ezetimibe

## Completion date

31/07/2006

# **Eligibility**

## Key inclusion criteria

- 1. Men and women greater than 18 years of age with LDL-C greater than or equal to 130 mg/dl
- 2. Have not received any cholesterol lowering medication for 8 weeks
- 3. Patients with coronary heart disease or coronary heart disease risk equivalents and with documented intolerance or reluctance to take Hydroxamethylglutaryl-CoA (HMG-CoA) reductase inhibitors will be included, however, patients being treated with and who are tolerant of HMG-CoA reductase inhibitors will not be considered

## Participant type(s)

**Patient** 

## Healthy volunteers allowed

No

## Age group

Adult

## Lower age limit

18 years

### Sex

All

## Key exclusion criteria

- 1. Plasma triglycerides >400 mg/dl
- 2. Congestive Heart Failure (CHF) with New York Heart Association (NYHA) class 3 or 4
- 3. Hemoglobin A1C >9%
- 4. Ileal bypass or gastrointestinal (GI) disorder that can impair absorption of study drugs
- 5. Impaired renal function aspartate aminotransferase (AST) or alanine transaminase (ALT) >2 times the upper limit of normal
- 6. Uncontrolled endocrine disorder
- 7. Alcohol consumption >14 drinks per week
- 8. Lipid lowering medication within 8 weeks
- 9. Treatment with oral corticosteroids, immunosuppressants, androgens or warfarin

#### Date of first enrolment

10/10/2005

#### Date of final enrolment

## Locations

## Countries of recruitment

United States of America

**Study participating centre 4675 Main Street**Bridgeport
United States of America
06606

# Sponsor information

## Organisation

Connecticut Clinical Research LLC (USA)

# Funder(s)

## Funder type

Industry

## **Funder Name**

Connecticut Clinical Research, LLC

## **Results and Publications**

Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration